Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439585 | 1.00 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 | |
| SCHEMBL29279251 | 1.00 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 | |
| SCHEMBL29279227 | 1.00 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 | |
| SCHEMBL26791478 | 1.00 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 | |
| SCHEMBL1841553 | 1.00 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 | |
| SCHEMBL1439647 | 1.00 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 | |
| SCHEMBL1439525 | 0.88 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 | |
| SCHEMBL1439523 | 0.88 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 | |
| SCHEMBL12812125 | 0.87 | BTK (0.37) | HSD17B10SMN1; SMN2NR1H2BTKPOLB | |
| SCHEMBL27157979 | 0.87 | SMN1; SMN2 (0.44) | HSD17B10SMN1; SMN2NR1H2BTKCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391926-A1 | SPIROINDOLINONE COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC | 2024-11-28 | — | — | US | disclosed |
| EP-4351569-A2 | SPIROINDOLINONE COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117597120-A | Spiroindolone compounds as Kv1.3 potassium Shaker channel blockers | D·E·萧尔研究有限责任公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2022251561-A2 | SPIROINDOLINONE COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2012101063-A1 | N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101064-A1 | N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2473499-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473505-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-7304165-B2 | Oligomers and polymers of di-substituted cyclic imino carboxylic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-6914048-B2 | Method for delivery of molecules to intracellular targets | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040152133-A1 | Oligomers and polymers of di-substituted cyclic imino carboxylic acids | GELLMAN SAMUEL H (US) | 2004-08-05 | — | — | US | disclosed |
| US-6727368-B1 | PYRROLIDINE-3-CARBOXYLIC ACID MONOMERS; POLYLACTAMS; COMBINATORIAL LIBRARIES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-04-27 | — | — | US | disclosed |
| US-6710186-B2 | CONFORMATIONALLY-RESTRICTED; ANALOGOUS TO POLY(PROLINE) II HELICAL STRUCTURE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-03-23 | — | — | US | disclosed |
| US-20030119189-A1 | Method for delivery of molecules to intracellular targets | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-06-26 | — | — | US | disclosed |
| WO-2003024477-A1 | METHOD FOR DELIVERY OF MOLECULES TO INTRACELLULAR TARGETS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20020032334-A1 | Oligomers and polymers of di-substituted cyclic imino carboxylic acids | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032334-A1 | Oligomers and polymers of di-substituted cyclic imino carboxylic acids | PCNA, PAICS, INHA | HSD17B10 1745/4885SMN1; SMN2 1138/4885NR1H2 4105/4885 |
| US-20040152133-A1 | Oligomers and polymers of di-substituted cyclic imino carboxylic acids | PCNA, PAICS, INHA | HSD17B10 1745/4885SMN1; SMN2 1138/4885NR1H2 4105/4885 |
| US-20240391926-A1 | SPIROINDOLINONE COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNK3, KCNJ2, KCND3 | HSD17B10 951/4885SMN1; SMN2 2357/4885NR1H2 1133/4885 |
| US-20030119189-A1 | Method for delivery of molecules to intracellular targets | DNPEP, SLC7A1, PHAX | HSD17B10 3928/4885SMN1; SMN2 2070/4885NR1H2 2575/4885 |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | HSD17B10 2246/4885SMN1; SMN2 2827/4885NR1H2 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.